PT - JOURNAL ARTICLE AU - Gater, Laura ED - Nauck, Michael TI - New Therapies: Vildagliptin DP - 2006 Sep 01 TA - MD Conference Express PG - 16--16 VI - 6 IP - 2 4099 - http://mdc.sagepub.com/content/6/2/16.short 4100 - http://mdc.sagepub.com/content/6/2/16.full AB - Vildagliptin, is a dipeptdyl peptidase 4 (DPP-4) inhibitor; DPP-4 is the enzyme that degrades glucagon-like peptide-1 (GLP-1). GLP-1 triggers glucose dependent insulin secretion, inhibits the secretion of glucagon, slows gastric emptying, and influences satiety. GLP-1 has a very short half-life, so by inhibiting the action of DPP-4, GLP-1 remains in its active form for a longer period. This article discusses updates on vildagliptin.